


IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A compound of formula (I), their analogs, their derivatives, their tautomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, and their pharmaceutically acceptable compositions, wherein G represents ~~substituted or unsubstituted, single or fused groups selected from aryl group, heteroaryl or heterocyclic groups containing one or more heteroatom selected from O, S, N;~~ preferably, G represents the groups one of A, B, C, D, E, or [[&]] F as described below:



R₁ represents hydrogen, substituted or unsubstituted groups selected the group consisting of from alkyl, aralkyl, acyl, alkylsulfonyl, and arylsulfonyl groups; R₂ represents alkyl, aralkyl, alkoxy or -NHR where R represents hydrogen or a lower alkyl group groups which may be suitably substituted; X₁, X₂, X₃, and X₄ may be same or different and represent hydrogen, cyano, nitro, halo, carboxyl, formyl, hydrazino, azido, amino, thio, hydroxy, or a substituted or unsubstituted group groups selected from the group consisting of alkyl which may be linear or branched, alkenyl, cycloalkyl, alkoxy, cycloalkoxy, cycloalkoxyalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, carboxyalkyl, haloalkyl, aminoalkyl, cyanoalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylalkyl, acyl, acyloxy, acyloxyalkyl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aralkenyl, acylamino, alkylamino, dialkylamino, aralkylamino,

- 4 -

3. (currently amended) The ~~[[A]]~~ compound as claimed in claim 1, ~~wherein the~~ where suitable substituents on X₁, X₂, X₃, and X₄ represent a ~~are selected from~~ cyano, nitro, halo, carboxyl, hydrazino, azido, formyl, amino, thio, hydroxy or substituted or unsubstituted group groups selected from the group consisting of alkyl which may be linear or branched, alkoxy, alkoxycarbonyl, acyl, acylamino, acyloxy, hydrazinoalkyl, alkylhydrazido, carboxyalkyl, haloalkyl, aminoalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, alkoxycarbonyl, and amidino groups.

4. (currently amended) The ~~[[A]]~~ compound as claimed in ~~according to~~ claim 1, wherein the pharmaceutically acceptable salts are salts of tartaric acid, mandelic acid, fumaric acid, malic acid, lactic acid, maleic acid, salicylic acid, citric acid, ascorbic acid, benzene sulfonic acid, p-toluene sulfonic acid, hydroxynaphthoic acid, methane sulfonic acid, acetic acid, benzoic acid, succinic acid, palmitic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or ~~[[&]]~~ nitric acid.

5. (currently amended) A pharmaceutical composition comprising one or more compounds as claimed in claim ~~Claim~~ 1 or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable carrier, diluent, excipient, ~~excipients~~ or solvate.

6. (currently amended) The ~~[[A]]~~ pharmaceutical composition as claimed in ~~according to~~ claim 1, in the form of a tablet, capsule, powder, granule, syrup, solution, or suspension.

7. (currently amended) A pharmaceutical composition which comprises~~[[,]]~~ a pharmaceutically-acceptable salt as claimed in ~~compound according to~~ claim 4, ~~as an~~ active ingredient and a pharmaceutically-acceptable carrier, diluent, excipient, ~~excipients~~ or solvate.

8. (currently amended) The [[A]] pharmaceutical composition as claimed in which
~~comprises, a compound according to claim 7~~ [[4]], in the form of a tablet, capsule,
powder, granule, syrup, solution, or suspension.

9. (currently amended) A method of treating inflammation or an inflammation-associated
disorder in a subject, said method comprising treating the subject having or susceptible
to such disorder with a therapeutically-effective amount of a compound as claimed in
[[of]] claim 1 or a pharmaceutically acceptable salt thereof.

10. (currently amended) The method as claimed in claim 9, wherein the compound is
administered orally, nasally, parenterally, topically, transdermally, or rectally.

11. (currently amended) A method of treating inflammation or an inflammation-
associated disorder in a subject, said method comprising treating the subject having or
susceptible to such disorder with a therapeutically-effective amount of a
pharmaceutically-acceptable salt as claimed in compound of claim 4.

12. (currently amended) The method as claimed in claim 11, wherein the
pharmaceutically-acceptable salt compound is administered orally, nasally, parenterally,
topically, transdermally, or rectally.

13. (currently amended) The [[A]] compound as claimed in according to claim 1 which is
selected from the group consisting of:

5-(4-Fluorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Chlorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Methylphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
1-(4-methylsulfoximinyphenyl)-5-(4-*n*-propoxyphenyl)- 3-trifluoromethyl-1H-pyrazole;
5-(4-Ethoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Hydroxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;

5-(3-Chloro-4-fluorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3,4-Difluorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Fluoro-3-methylphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Methoxy-3-methylphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Chloro-4-methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Bromo-4-methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Fluoro-4-methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Methoxy-4-methylphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
1-(2-Fluoro-4-methylsulfoximinyphenyl)-5-(4-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazole;
1-(3-Fluoro-4-methylsulfoximinyphenyl)-5-(4-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazole;
1-(4-Methylsulfoximinyphenyl)-5-phenyl-3-trifluoromethyl-1H-pyrazole;
1-(4-Methylsulfoximinyphenyl)-5-(1-naphthyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Methoxyphenyl)-3-methyl-1-(4-methylsulfoximinyphenyl)-1H-pyrazole;
1-(4-Methylsulfoximinyphenyl)-5-(4-nitrophenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3,5-Difluoro-4-Methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Hydroxy-4-methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-1H-pyrazole-3-carboxylicacid;
3-(Hydroxymethyl)-5-(4-Methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-1H-pyrazole;

5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazol-3-ylmethylhydrogen sulphate;
5-{4-(2-Hydroxy-ethoxy)phenyl}-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
1-(4-Methylsulfoximinylphenyl)-5-(4-pyridyl)-3-trifluoromethyl-1H-pyrazole;
1-(4-Methylsulfoximinylphenyl)-5-(3-pyridyl)-3-trifluoromethyl-1H-pyrazole;
1-(4-Methylsulfoximinylphenyl)-5-(2-pyridyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Isopropoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
1-(4-Methylsulfoximinylphenyl)-5-(2-thiophenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Methylsulfoxyminyphenyl)-1-phenyl-3-trifluoromethyl-1H-pyrazole; [[.]]
1-(4-Methoxyphenyl)-5-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-Ethyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole;
5-Methoxymethyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole;
3-(4-Fluorophenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole;
3-(4-Chlorophenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole;
3-Ethyl-4-(4-methylsulfoximinylphenyl)-5-phenyl-isoxazole;
5-Chloro-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole;
5-Methyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole;
3-(4-Methoxyphenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole;
3-(3,4-Dichlorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;
3-(4-Chlorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;
3-Phenyl-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;
3-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;
3-(3,4-Dimethoxyphenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;
3-(4-Methoxyphenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;
3-(4-Methylphenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;
5-Chloro-3-(4-methylsulfoximinylphenyl)-6'-methyl-[2,3']bipyridinyl;
5-Chloro-3-(4-methylsulfoximinylphenyl)-[2,3']bipyridinyl;
3-(3-Fluorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-thiazol-2-one;
3-(3,4-Dichlorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-oxazol-2-one;

3-(3,4-Dichlorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-thiazol-2-one;
3-(2-Fluorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-oxazol-2-one;
3-(4-Bromophenyl)-4-(4-methylsulfoximinylphenyl)-3H-oxazol-2-one;
4-(4-Methylsulfoximinylphenyl)-3-phenyl-3H-oxazol-2-one;
3-(3,4-Dichlorophenyl)-4-[4-(N-chloroacetyl) methylsulfoximinyl-phenyl]-3H-oxazol-2-one;
3-(3,4-Dichlorophenyl)-4-[4-(N-acetyl) methylsulfoximinyl-phenyl]-3H-oxazol-2-one;
3-(3,4-Dichlorophenyl)-4-[4-(N-methylsulfonyl)methylsulfoximinyl-phenyl]-3H-oxazol-2-one;
3-(3,4-Dichlorophenyl)-4-[4-{N-(4-methylphenyl)sulfonyl}-methylsulfoximinyl-phenyl]-3H-oxazol-2-one; and
pharmaceutically-acceptable salts thereof.

14. (currently amended) The [[A]] compound as claimed in ~~according to~~ claim 13, wherein the pharmaceutically acceptable salts are salts of tartaric acid, mandelic acid, fumaric acid, malic acid, lactic acid, maleic acid, salicylic acid, citric acid, ascorbic acid, benzene sulfonic acid, p-toluene sulfonic acid, hydroxynaphthoic acid, methane sulfonic acid, acetic acid, benzoic acid, succinic acid, palmitic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or [[&]] nitric acid.

15. (currently amended) A pharmaceutical composition, which comprises a compound or pharmaceutically-acceptable salt thereof as claimed defined in claim 13 ~~claims 13 & 44~~, and a pharmaceutically acceptable carrier, diluent, excipient, ~~diluents or excipients~~ or solvate.


16. (currently amended) The [[A]] pharmaceutical composition as claimed in claim 15, in the form of a tablet, capsule, powder, granules, syrup, solution, or suspension.

17. (currently amended) A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising treating the subject having or

susceptible to such disorder with a therapeutically-effective amount of a compound of
~~claims 13-16~~ or [[a]] pharmaceutically acceptable salt thereof as claimed in claim 13.


Claim 18 (canceled)

19. (currently amended) A process for preparing a compound ~~the preparation of~~
~~compounds~~ of formula (I),




(I)

wherein Where G represents ~~substituted or unsubstituted, single or fused groups~~
~~selected from aryl group, heteroaryl or heterocyclic groups containing one or more~~
~~heteroatom selected from O, S, N; one of A, B, C, D, E, or F as described below:~~




R_1 represents hydrogen, substituted or unsubstituted groups selected from the group
consisting of alkyl, aralkyl, acyl, alkylsulfonyl, and arylsulfonyl groups; R_2 represents
 alkyl, aralkyl, or $-NHR$ or $-OR$ where R represents hydrogen or a lower alkyl group
~~groups~~ which may be suitably substituted; X_1 , X_2 , X_3 , and X_4 may be same or different
 and represent hydrogen, cyano, nitro, halo, carboxyl, formyl, hydrazino, azido, amino,

20. (currently amended) The process as claimed in claim 19 further comprising converting the compound of formula (I) to its pharmaceutically-acceptable salt, where the groups representing G are preferably selected from A, B, C, D, E & F as described below, and all other symbols are as defined earlier.




21. (currently amended) A process for preparing a compound of general formula (P) as defined in claim 19 ~~claims 19 & 20~~, said process comprising which comprises:

- i. reacting a haloketone of formula (II) with a compound of formula (III) to obtain a mercapto compound of formula (P),




where G represents




and all other symbols are as defined earlier; [[.]]

- ii. converting an [[the]] oxime of formula (VII) to a mercapto compound of formula (P),




where G represents




and all other symbols are as defined earlier;

- iii. reacting a [[the]] hydrazine of formula (XI) with a 1,3-diketone of formula (XII) to form a [[the]] mercapto compound of formula (P),




where G represents




and all other symbols are as defined earlier; [[.]]

- iv. reacting a compound of formula (XVII) with a compound of formula (XVIII) to form a mercapto compound of formula (P),




where G represents




and all other symbols are as defined earlier;

- v. reacting a compound of formula (XXI) with a compound of formula (XXII) to form a ~~get~~ mercapto compound of formula (P),



where G represents



and all other symbols are as defined earlier.